- Home
- CISS vs INBS Comparison
CISS vs INBS Comparison
Compare CISS & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | INBS |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CISS | INBS |
|---|---|---|
| Price | $0.23 | $6.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 40.1K |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,613,149.00 | $3,292,042.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.16 | ★ N/A |
| Revenue Growth | N/A | ★ 3.26 |
| 52 Week Low | $0.20 | $5.09 |
| 52 Week High | $11.52 | $27.50 |
Technical Indicators
Market Signals| Indicator | CISS | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 16.93 | 84.04 |
| Support Level | $0.20 | $0.54 |
| Resistance Level | $0.24 | $7.25 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | -0.13 | 0.70 |
| Stochastic Oscillator | 1.58 | 83.55 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.